Worldwide cancer is the leading cause of death; leukocytes within tumors and at the sites of chronic inflammation provided the first indication of a possible link between inflammation and cancer. Inflammation plays a crucial role at different stages of tumor growth via. transcription factors and inflammatory mediators such as TNF, IL’s, chemokines COX-2, STAT3and NF-κB. Nuclear factor-kappa B (NF-κB) has been one of the most extensively investigated transcription factors for its role in cancers. The NF-κB signaling pathways are vital in the initiation and progression of cancer which can act as a node of pharmacological interference in the management of tumor. However, NF-κB is an essential player in the immune response against various cancer developments; hence inhibition of NF-κB seems to be always important in the treatment of various malignancies. The application of an NF-κB inhibitor may prove useful in anticancer therapy by converting anti-apoptosis effect of NF-κB into apoptotic nature. Therefore, current review focuses on the role of NF-κB in Inflammation Induced cancer (IIC) and prospects for developing of a novel treatment for inflammation-related cancer.